ERBB2 and cancer: A phase I dose escalation study for ZW49 for locally advanced or metastatic HER2-expressing cancers was initiated, with preliminary results determining a recommended dose as 2.5 mg/kg Q3W (ORR = 28%; DCR = 72%) (NCT03821233) [154].